Quick Answer
AbCellera Biologics Inc. reported Diluted EPS of $0.49 per share (loss) for fiscal year 2025.
AbCellera Biologics Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.49 | +10.9% |
| 2024 | -$0.55 | -7.8% |
| 2023 | -$0.51 | -202.0% |
| 2022 | $0.50 | +4.2% |
| 2021 | $0.48 | +6.7% |
| 2020 | $0.45 | +4600.0% |
| 2019 | -$0.01 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.19 | -11.8% | -58.3% |
| June 30, 2025 | -$0.12 | +7.7% | +20.0% |
| March 31, 2025 | -$0.15 | -7.1% | +11.8% |
| September 30, 2024 | -$0.17 | -70.0% | -30.8% |
| June 30, 2024 | -$0.13 | -18.2% | +7.1% |
| March 31, 2024 | -$0.14 | +0.0% | -40.0% |
| September 30, 2023 | -$0.10 | -225.0% | +9.1% |
| June 30, 2023 | -$0.11 | -450.0% | +21.4% |
- AbCellera Biologics Inc. showed an increase of +10.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, AbCellera Biologics Inc.’s diluted eps has declined by 4800.0% (from $0.01 per share (loss) to $0.49 per share (loss)).
- The most recent figure is from AbCellera Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: